Cite
HARVARD Citation
Hong, D. et al. (n.d.). 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors. Journal for immunotherapy of cancer. pp. A231-A232. [Online].